Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · IEX Real-Time Price · USD
1.030
-0.010 (-0.96%)
At close: May 17, 2024, 4:00 PM
1.020
-0.010 (-0.97%)
After-hours: May 17, 2024, 5:11 PM EDT

Company Description

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.

Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments.

The company was incorporated in 2007 and is headquartered in San Diego, California.

Organovo Holdings, Inc.
Organovo Holdings logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Keith E. Murphy

Contact Details

Address:
11555 Sorrento Valley Road, Suite 100
San Diego, California 92121
United States
Phone 858-224-1000
Website organovo.com

Stock Details

Ticker Symbol ONVO
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001497253
CUSIP Number 68620A203
ISIN Number US68620A2033
Employer ID 27-1488943
SIC Code 2836

Key Executives

Name Position
Keith E. Murphy Company Secretary and Executive Chairman
Vaidehi Joshi Director of Discovery Biology and Director
Thomas P. Hess CPA, MBA President and Chief Financial Officer
Dr. Curtis M. Tyree Ph.D. Senior Vice President of Strategy and Business Development

Latest SEC Filings

Date Type Title
May 14, 2024 424B4 Prospectus
May 13, 2024 8-K Current Report
May 10, 2024 424B4 Prospectus
May 8, 2024 EFFECT Notice of Effectiveness
May 1, 2024 8-K Current Report
Apr 30, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 23, 2024 8-K Current Report
Apr 12, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 EFFECT Notice of Effectiveness